Vertex Pharmaceuticals Announces Acquisition of Crinetics Pharmaceuticals for $10 billion
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has entered into a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in a cash‑only transaction valued at approximately $10 billion, or $85.00 per share. The deal, approved unanimously by both boards, is expected to close in the third quarter of 2026 and will add Crinetics’ portfolio of endocrine therapeutics to Vertex’s innovation pipeline.
Strategic Rationale
Crinetics’ flagship product, PALSONIFY (paltusotine), is the first and only once‑daily oral therapy for adults with acromegaly. The drug received U.S. FDA approval in September 2025, European Medicines Agency approval in the same year, and is under review by other global regulators. Since launch, PALSONIFY has shown strong early commercial momentum, including rapid disease control and normalization of key biomarkers in both treatment‑experienced and untreated patients. Demand has expanded across all patient segments, and reimbursement coverage has increased, positioning the product to reshape the acromegaly treatment paradigm.
Crinetics’ most advanced pipeline asset, atumelnant, is a once‑daily oral adrenocorticotropic hormone (ACTH) receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia (CAH). Phase 2 data indicate that atumelnant can normalize androgen levels while permitting physiologic glucocorticoid replacement, addressing a critical unmet need in the rare disease. The compound has demonstrated a favorable safety profile with no treatment‑related severe or serious adverse events reported to date.
The acquisition is projected to deliver an estimated $5 billion peak sales opportunity, enhancing Vertex’s revenue growth and long‑term earnings profile. It also accelerates Vertex’s expansion into endocrinology and oncology, areas where the company seeks to deepen its therapeutic footprint.
Transaction Details
| Item | Value |
|---|---|
| Purchase price | $85.00 per share (cash) |
| Total equity value | ~ $10.0 billion |
| Net value (after estimated cash acquired) | ~ $8.8 billion |
| Closing period | Q3 2026 |
Vertex will host an investor call on July 6 at 4:30 p.m. ET to discuss the transaction and its implications for the company’s strategy.
Company Backgrounds
- Vertex Pharmaceuticals: A global biopharmaceutical company focused on developing and commercializing therapies for serious diseases, including cystic fibrosis and oncology.
- Crinetics Pharmaceuticals: A clinical‑stage biotech based in San Diego, California, specializing in endocrine disease therapeutics and cancers. As of July 1 2026, its share price was $42.23, with a 52‑week range of $25.83 to $57.99 and a market capitalization of $4.45 billion.
The acquisition aligns with Vertex’s objective to broaden its product pipeline and capture high‑potential markets in endocrine and rare disease therapeutics.
